4C Medical Technologies has won the Best Technology Parade Presentation award—at the 2017 Innovations in Cardiovascular Interventions (ICI) meeting (3–5 December, Tel Aviv, Israel)—for its transcatheter device for treating mitral regurgitation.
At the ICI meeting (Hôpital du Sacré-Coeur de Montréal, Montréal, Canada) gave the presentation “A novel transcatheter mitral regurgitation technology system (4C valve)”. In the presentation, he explained how the 4C valve may extend transcatheter mitral valve implantation (TMVI) therapy to patients who would be ineligible for alternative TMVI procedures.
Généreux says: “The progress made by the 4C Medical team is astonishing. The engineering team’s creative yet practical approach has enabled them to drive the development of the 4C valve at a very rapid pace. Because the 4C valve is placed and anchored entirely in the left atrium and does not rely on or interact with the dynamic and irregular anatomy of the mitral annulus and left ventricle, it can be used in a much broader patient population as compared to other TMVI devices. This will lead to quicker patient enrolment in future clinical trials and provide much needed treatment to mitral regurgitation patients.”
“We are pleased that the ICI organisers recognized the uniqueness of the 4C valve, our transcatheter mitral valve technology which uses a supra-annular, atrial-only fixation approach. This award, from one of the most respected internationally organised innovation conferences, further validates our team’s momentum towards the early feasibility study, which is targeted to start by the end of 2018,” says Robert Thatcher, president and chief executive officer of 4C Medical.